Arthur He
Stock Analyst at HC Wainwright & Co.
(2.14)
# 3,012
Out of 4,963 analysts
62
Total ratings
45.9%
Success rate
-5.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintains: Buy | $8 → $7 | $2.22 | +215.32% | 11 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Maintains: Neutral | $1.5 → $1.24 | $1.55 | -19.74% | 11 | Aug 5, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $12.09 | +40.61% | 1 | Jul 30, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | n/a | $0.07 | - | 7 | Jul 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $29.36 | +308.72% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.63 | +255.24% | 10 | Jun 17, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $75 → $85 | $22.27 | +281.77% | 2 | Jun 2, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.44 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.42 | - | 8 | Mar 31, 2025 |
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $2.22
Upside: +215.32%
LAVA Therapeutics
Aug 5, 2025
Maintains: Neutral
Price Target: $1.5 → $1.24
Current: $1.55
Upside: -19.74%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $12.09
Upside: +40.61%
Adaptimmune Therapeutics
Jul 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.07
Upside: -
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $29.36
Upside: +308.72%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.63
Upside: +255.24%
Vera Therapeutics
Jun 2, 2025
Maintains: Buy
Price Target: $75 → $85
Current: $22.27
Upside: +281.77%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.44
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.42
Upside: -